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1. Introduction 
The successful establishment of human embryonic stem cells (hESCs) in culture (Thomson et 
al., 1998) has raised unprecedented public interest and expectation of treating intractable 
diseases such as diabetes, spinal cord injuries, neurodegenerative and cardiovascular 
diseases. Much of this enthusiasm was predicated on the unlimited self-renewal capacity of 
hESCs and their remarkable plasticity in differentiating into every cell type in our body. 
These features presented the tantalizing possibility of an unlimited cell source in 
regenerative medicine to generate any tissues to replace injured or diseased tissues. 
However, translating the potential of hESC into therapies has been challenging. Although 
translation of hESC has been severely impeded by social and political constraints placed on 
hESC research through ethical and religious concerns over the destruction of viable 
blastocysts during hESC isolation, the main challenges have been safety and technical 
issues.  
2. Challenges in ESC therapy 
2.1 Overcoming tumor formation 
The two defining characteristics of ESCs are: 1) their pluripotency, or the potential to 
differentiate into all cell types in the adult body; and 2) their unlimited self-renewal 
capacity, or the ability to remain in an undifferentiated state and divide indefinitely. For 
mESCs, pluripotency is often demonstrated by the production of mESC-derived animals 
through germline transmission by chimeras resulting from injection of the cells into 
blastocysts or through tetraploid complementation. In hESCs, proof of pluripotency has 
been limited to formation of teratomas or teratocarcinomas, which are tumors composed of 
randomly distributed tissues from the three primordial germ layers in immunologically 
incompetent mice (Lensch et al., 2007). Karyotypically normal, low passage hESCs form 
benign teratomas that do not contain undifferentiated tissues and are less invasive (Blum et 
al., 2009; Reubinoff et al., 2000; Thomson et al., 1998) while high passage hESCs which have 
become karyotypically abnormal give rise to highly invasive, malignant teratocarcinomas 
(Herszfeld et al., 2006; Plaia et al., 2006; Werbowetski-Ogilvie et al., 2009; Yang et al., 2008).  
Pluripotency coupled with unlimited self-renewal not only define ESCs, they are also the 
main appeal of ESC as the cell source for regenerative medicine but at the same time, pose 
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significant challenges to the transplantation of differentiated ESCs to replace injured or 
diseased tissues. The propensity of ESC to differentiate into teratomas necessitates the need 
to eliminate any residual ESCs in the differentiated cell preparation. There have been many 
strategies to eliminate residual ESCs or enhance the purity of differentiated ESC 
preparations. The use of heterologous selectable gene markers such as antibiotic resistance 
gene or fluorescent protein markers (Klug et al., 1996; M. Li et al., 1998; Muller et al., 2000; 
Soria et al., 2000) is generally not a strategy of choice as this could introduce potentially 
deleterious gene mutations. Most of the strategies centered around the use of endogenous 
markers that are unique or highly expressed on ESCs and not on their differentiated 
progeny. For example, SSEA-4 and TRA-1-60 which are highly expressed on hESCs have 
shown to be highly efficient in physically removing contaminating ESCs by magnetic or 
fluorescence-activated cell sorters (MACS or FACS) (Fong et al., 2009b). Another strategy 
exploit the flotation density of cell on discontinuous density gradients such as Puresperm- 
or Percoll-based gradients (Fong et al., 2009a). Using a relatively novel strategy, Choo et al. 
has raised antibodies against undifferentiated hESCs (Choo et al., 2008) and identified an 
antibody that was cytotoxic against hESCs by oncosis. This antibody was an IgM that 
recognizes podocalyxin-like protein-1(PODXL).  hESCs that were treated with mAB 84 did 
not form teratoma when transplanted into SCID mice even after 18-24 weeks. Therefore, 
there are viable technologies to remove or reduce residual hESCs in differentiated hESC 
preparation and mitigate the risk of teratoma formation in patients receiving hESC-based 
cell therapy.      
2.2 Overcoming immunorejection 
Like all tissue transplants, hESC-based cell therapy will have to circumvent host immune 
rejection to engraft in the recipients. One proposed strategy was to establish ESC 
repositories with lines expressing the combinations of HLA molecules that are compatible 
with HLA haplotypes present in the population (Nakajima et al., 2007; Taylor et al., 2005). 
Alternatively, the host’s immune system could be manipulated to induce tolerance to 
foreign tissues by ablation of donor-reactive T cell in the thymus, generation of tolerogenic 
dendritic cells and induction of Treg cells [reviewed in (Chidgey et al., 2008)]. However, with 
the development of induced pluripotent stem cell technology that makes the creation of 
“patient-specific” pluripotent cells containing the same genetic material as the recipient a 
highly viable and practical option, the issue of host rejection has become a non issue.  
The quest to create “patient-specific” pluripotent cells began with therapeutic cloning or 
somatic cell nuclear transfer (SCNT) where the diploid nucleus of a somatic cell was injected 
into a haploid enucleated egg to be reprogrammed by soluble factors in the host cell. Upon 
stimulation, the re-programmed cell divides to form a blastocyst with an inner cell mass that 
has identical nuclear genetic composition as the nucleus donor. Although this approach has 
worked to generate ESCs from different animals such as mice, rabbits, cats, sheep, cattle, 
pigs, goats [reviewed in (Wilmut et al., 2002)] and even primates (Byrne et al., 2007), no 
hESC has been generated through this approach as it remains a highly inefficient process 
and the use of human oocytes is ethically controversial (French et al., 2008; J. Li et al., 2009b). 
ESCs generated through SCNT are in principle, heterogeneous in their genetic composition 
as they contain nuclear DNA of the nucleus donor and mitochondrial DNA of the egg donor 
(Evans et al., 1999). This raises the possibility that SCNT-derived ESCs could be rejected by 
the innate immune system of the host with which the ESCs share the same nuclear but not 
mitochondrial genetic material (Ishikawa et al., 2010).  
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Fig. 1. Mitigating tumor formation and immune rejection. Two of the major challenges to the 
translation of ESCs into clinical applications are teratoma formation by residual 
undifferentiated ESCs in the cell preparation and immune rejection of ESC-derived cells or 
tissues due to incompatible HLA profiles of ESC and recipient. To mitigate the risk of 
teratoma formation, several methods to remove residual hESCs have been developed using 
either physical or biological methods. Some of the physical separation methods are based on 
magnetic- or fluorescence-activated cell sorters (MACS or FACS) that sort against cells with 
ESC-associated surface markers, SSEA-4 and TRA-1-60 or on cellular density using 
discontinuous gradients of Percoll or PureSperm. Alternatively, residual ESCs can be 
destroyed using a cytotoxic antibody (mAb 84) specific for undifferentiated hESCs. To 
prevent immune rejection, one strategy proposed the establishment of ESC repositories to 
carry lines expressing HLA combinations compatible with all possible haplotypes in the 
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population. Alternatively, donor cell tolerance can be induced by manipulating host 
immune defenses, such as eliminating donor-reactive T cells in the thymus, generating 
tolerogenic dendritic cells and inducing Treg cells. An ideal approach would be to generate 
patient-specific ESCs. Some of early efforts include the use of somatic cell nuclear transfer 
(SCNT). More recently, induced pluripotent stem cell (iPSC) technology has enabled with 
great ease the generation of self pluripotent stem cells without the destruction of oocytes or 
embryos, hence bypassing ethical controversies. 
The breakthrough in creating “patient-specific” pluripotent cells was achieved when 
Yamanaka demonstrated  that the introduction of transcription factors which regulate ESC 
self-renewal, including Oct3/4 and Sox2 was sufficient to reprogram somatic cells into ES-
like cells (Takahashi & Yamanaka, 2006). These induced pluripotent stem cells (iPSCs) are 
karyotypically normal with gene expression profiles highly similar to ESCs and can 
differentiate into cells of all three germ layers (Takahashi et al., 2007; Yu et al., 2007). Apart 
from being patient-specific, the major attraction of iPSCs lies in their derivation from 
somatic tissues and not from ethically contentious tissues such as human oocytes or 
embryos. However, retroviral and lentiviral vectors were required to express the 
transcription factors for reprogramming  of the somatic cells and this carries a risk of 
insertional mutagenesis. To circumvent the need for viral vectors, non-viral genetic 
modification approaches were developed (Okita et al., 2008; Soldner et al., 2009; Woltjen et 
al., 2009). Recently iPSCs were obtained via a direct delivery of reprogramming factors into 
cells using poly-arginine protein transduction domains (Zhou et al., 2009) or mRNA (Plews 
et al., 2010), thereby circumventing any form of genetic manipulation. These improvements 
have essentially abrogated the issue of host/donor cell immune compatibility and 
considerably enhanced the prospects of generating patient-specific iPSCs for regenerative 
medicine. However, a recent study demonstrated that some hiPSC derivatives exhibit 
limited expansion capability, increased apoptosis and early cellular senescence as compared 
to their hESC-derived counterparts, raising doubts about the clinical value of this 
reprogramming technology (Feng et al., 2010). Also, it remains to be determined if the 
progeny of these cells, which are genetically identical to the reprogrammed cell, will trigger 
any immune response when reintegrated into the donor. 
2.3 ESC differentiation  
ESC owes its allure as the source of stem cells for regenerative medicine to two important 
potentials: 1) unlimited self-renewal potential and 2) the potential to differentiate into all the 
cell types in an adult. Unfortunately, the recent technological advances to circumvent the 
risks associated with transplantation of ESC-derived cells, namely teratoma formation and 
host immune rejection, were not matched by similar progress in differentiating hESCs into 
cells suitable for regenerative medicine.   In contrast to adult stem cells where hundreds of 
clinical trials have been conducted to evaluate their clinical efficacy, the first testing of a 
hESC-based therapeutic candidate has only just been initiated. In Oct 2010, Geron Corp 
announced the enrollment of the first patient to test the safety of human embryonic stem cell 
(hESC)-derived oligodendrocyte progenitor cells, GRNOPC1, in treating spinal cord injury. 
With the progress made in reducing the risk of teratoma formation by residual ESC in 
differentiated ESC preparations and the generation of patient-specific iPSC, the major 
impediment to the development of hESC-based cell therapies remains the general lack of 
progress in developing protocols for efficient and reproducible differentiation of hESCs into 
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clinically relevant cell types in sufficient quantity and purity suitable for transplantation 
studies in clinically relevant large animal models.  
The pluripotent differentiation potential of hESCs has always been predicated on their 
ability to form teratomas in immune-compromised animals and embryoid bodies consisting 
of tissues from the three germ layers. This ability suggest that differentiation of ESC into the 
various cell types in the adult animal was not contingent on the presence of an embryonic 
microenvironment. Instead, it relies on a rather minimal environment that did not support 
the pluripotent and self-renewing state of the ESCs and bore little resemblance to the 
dynamically evolving microenvironment of a developing embryo. Nevertheless, much effort 
to direct differentiation of hESCs into potentially therapeutic cell types have focused on the 
recapitulation of the embryonic microenvironment based on a yet to be tested rationale that 
the embryonic microenvironment represents the optimal micro-environment for directed in 
vitro differentiation of  ESC. 
2.3.1 Recapitulating embryonic development to induce lineage commitment  
Embryogenesis is a highly dynamic complex process that is still being unraveled despite 
years of intensive research and much progress in elucidating the molecular and cellular 
processes involved in formation of an embryo. From a developmental perspective, the ESC 
represents cells that were frozen in the developmental state of a late-stage embryo just prior 
to differentiation and lineage commitment. The ability of ESC to re-enter the developmental 
process and differentiate when returned to the micro-environment of a blastocyst has 
provided compelling impetus to use the developing embryo to guide and direct in vitro 
differentiation of ESC to a specific cell type. Much effort has therefore been devoted to 
identifying the molecular cues that were involved in the differentiation of pluripotent cells 
in the blastocyst into specific terminally differentiated cells. The underlying rationale has 
always been that a temporal and spatial recapitulation of these cues in vitro will direct 
differentiation of ESC towards a specific cell type. 
An early and critical phase of embryogenesis is gastrulation. During this process, the mono-
layered blastula undergoes a series of transformation to form the tri-layered gastrula. The 
formation of these three germ layers (endoderm, mesoderm and ectoderm) marks the first 
stage of cell fate determination. This is followed by organogenesis when tissues and organs 
are formed from further differentiation of the germ layers. The endoderm gives rise to the 
epithelia of the gut and respiratory system, and organs such as liver and pancreas; the 
mesoderm gives rise to muscles, the circulatory system, bone and connective tissues; and the 
ectoderm gives rise to the nervous system and the epidermis. Similarly, the initial step 
towards deriving functional cells and tissues from ESCs may involve germ layer induction 
in vitro. 
The first visible sign of gastrulation is the formation of the symmetry-breaking structure 
called the primitive streak (PS). Epiblast cells, which are derived from the inner cell mass, 
ingress through the PS to form the mesoderm and definitive endoderm. The remaining 
epiblast cells that do not ingress form the ectoderm. Many molecular factors have been 
implicated in this process and they include members of the large transforming growth factor 
β (TGFβ) and Wnt signaling families (Conlon et al., 1994; Hogan, 1996; Schier, 2003; 
Yamaguchi, 2001). Painstaking research has revealed some of the temporal and spatial 
effects of these factors during embryogenesis and many of these factors exerted similar 
effects on the differentiation of ESC cells. As reviewed by Murry and Keller (Murry & 
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Keller, 2008)], differentiation of ESCs into each of the three germ layers could be induced by 
the same factors known to induce them during gastrulation. For example,  Wnt, Nodal or 
BMP4 which have been shown to be important in the formation of epiblast cells in the PS of 
a developing embryo (Kispert & Herrmann, 1994) could similarly  induce the formation of 
PS-like cells from ESC (Kubo et al., 2004; Lindsley et al., 2006; Ng et al., 2005; Nostro et al., 
2008). As in gastrulation, exposure of the PS-like cells to high levels of Nodal further 
differentiate these cells to a Foxa2hi cells that are comparable to cells in the anterior PS that 
forms the definitive endoderm (D'Amour et al., 2005; Kubo et al., 2004). In contrast, 
exposure to Wnt, low level of activin (which activates Nodal) and BMP4 causes the PS-like 
cells to differentiate into a Flk-1+ posterior PS-equivalent population that forms the 
mesoderm (Nostro et al., 2008). Therefore, the three germ layers can be induced in ESCs by 
exposing the cells to factors known to be important in the formation of these three germ 
layers during embryogenesis. Further, by modulating these factors in a concentration and 
temporal manner that recapitulates early embryonic development, commitment of ESCs to 
one of the germ layers could be enhanced.  
2.3.2 Enhancing lineage commitment 
The intensive research efforts to induce a bias in differentiating pluripotent ESCs towards 
one of the germ layers would, in principle, enhance the subsequent production of specific 
tissue cell types of this germ layer e.g. muscles from mesoderm. However, enhancing 
commitment of differentiating ESC to one of the three germ layers may not be the limiting 
factor in generating clinically useful cell types in sufficient number and purity for 
therapeutic or screening applications. For example, the most efficient derivation of clinically 
useful cell types from ESC is neural cell types and not surprisingly, the first ESC-derived cell 
type to be clinically tested is oligodendrocytes. The relative efficiency of generating neurons, 
astrocytes and oligodendrocytes from ESC probably lies not in the ease of generating neural 
progenitor cells but in the relatively high expansion capacity of ESC-derived neural 
progenitor cells (Dottori & Pera, 2008; Studer, 2009). The high expansion capacity of neural 
progenitor cells would easily circumvent a limiting supply of rare neural progenitor cells 
formed during ESC differentiation and obviates the need to first bias differentiation of 
pluripotent ESCs towards an ectodermal germ lineage. Therefore, the rationale underlying 
the intensive research efforts to bias differentiating pluripotent ESCs towards one of the 
germ layers may be redundant at least for the derivation of neural cell types. Unlike 
ectodermal differentiation which is generally considered the default differentiation pathway 
for ESC, the derivation of mesodermal or endodermal cell types from ESC could still be 
enhanced by the recapitulation of early embryonic development processes to enhance 
mesodermal or endodermal commitment. 
2.3.3 Terminal differentiation of ESC 
In 2005, D'Amour et al reported the use of a multi-stage protocol that attempts to temporally 
recapitulate embryonic development for the differentiation of hESC into insulin-producing 
pancreatic cells for diabetes treatment. During this differentiation regime, they observed the 
formation of sequential transient cell populations with markers that mapped onto the 
developmental pathway of pancreatic endoderm. The final cell population representing 
pancreatic endoderm was transplanted in mice for further differentiation and maturation. 
When these transplanted animals were treated with streptozotocin, the induction of 
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hyperglycemia was attenuated. It was observed that some of the transplanted mice 
developed teratomas, suggesting the cell preparation was heterogenous and contaminated 
with ESCs that could differentiate into all cell types. In contrast, differentiation of mouse 
ESCs to insulin-producing cells is often a three-step protocol consisting of the formation of 
embryoid bodies, spontaneous differentiation into ecto-, endo- and mesoderm lineages and 
finally induction of pancreatic differentiation (Schroeder et al., 2006). However, the cell 
populations generated using this protocol have low insulin content. Using an approach that 
combines elements from this protocol and that used in neural differentiation, we first 
derived highly expansible E-RoSH cell lines with meso-endoderm potential  from 
spontaneously differentiating EBs (Lian et al., 2006; Yin et al., 2004). Like neural stem cells, 
these E-RoSH cell lines are highly proliferative and provide unlimited supply of cells for 
differentiation. Serum starvation and nicotinamide supplementation induce differentiation 
of E-RoSH cells to form a heterogenous, insulin-producing culture. Limiting dilution of such 
cultures yielded independently derived clonal insulin-producing ERoSHK cell lines. These 
cells contain equimolar of insulin and C-peptide that was stably maintained over 30 
passages at a high concentration of 300-500 pmol/106 cells. The insulin-producing ERoSHK 
cells resemble pancreatic cells and display the defining functional properties of bona fide 
pancreatic beta cells (G. Li et al., 2009a). They synthesize and store insulin in typical 
intracellular vesicles. Under stimulation by secretagogues such as glucose, tolbutamide and 
glibenclamide, these cells close their ATP-sensitive K+ channels, leading to membrane 
depolarization, opening of Ca2+ channels and the subsequent release of insulin and C-
peptide in equimolar ratio, a mechanism resembling that of primary beta cells. Most 
importantly, these cells can reverse hyperglycemia when grafted into streptozotocin-treated 
mice. Relative to their progenitor E-RoSH cells, ERoSHK cells also exhibit enhanced activity 
in biochemical pathways that are also highly characteristic of beta cells such as the pentose 
phosphate pathway, clathrin-mediated endocytosis and PPAR signaling (T. S. Chen et al., 
2010).  Importantly, transplantation of ERoSHK cells in hyperglycemic streptozotocin-
treated mice reverses the hyperglycemia and removal of the transplanted cells restores the 
hyperglycemia. The transplanted cells do not form teratomas. Together, these studies 
illustrated the diversity of approaches that have been taken to differentiate ESCs to insulin-
producing cells and the relative potential of each approach in generating the desired end 
product on a scale to support potential therapeutic application. They also prompted doubts 
on the need to recapitulate the precise developmental pathway when differentiating ESC. 
This question was previously raised by Burns et al (Burns et al., 2004). From their 
perspective, developmental events directing duodenal endoderm towards an insulin-
expressing β-cell phenotype are the result of millions of years of evolutionary selection, 
driven by environmental pressures rather than by conscious design. Therefore, instead of 
mapping experimental protocols on to the known developmental pathways of pancreatic 
endocrine cells, they proposed that conscious design may be a less circuitous route to arrive 
at the same end-point. However, in lieu of known developmental pathways, there is no 
obvious source to guide and rationalize such a design. In essence, a conscious design would 
inevitably have to be an empirical approach of careful observation, trial and error, and high 
throughput screens.  
2.3.4 Empirical differentiation of ESC 
Despite a pervasive belief that a high fidelity recapitulation of developmental process 
represents the best strategy for efficient differentiation of pluripotent stem cells to 
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therapeutically useful cell types , the two human ESC-derived cell types ready for testing in 
man were derived by empirically formulated protocols. Fortuitously, some elements in 
these protocols were subsequently found to map onto similar pathways in embryonic 
development. 
In the basic protocol for deriving Geron Corporation’s GRNOPC1 which is already in Phase 
I clinical trial, one of the key elements in inducing neural commitment in ESCs to form 
neurospheres is retinoic acid (RA) (Nistor et al., 2005). RA was first observed to be an   
inducer of neural differentiation in embryonal carcinoma cells (ECs) (Jones-Villeneuve et al., 
1982) before the first retinoic acid receptor (now known as RARa1) was cloned in 1987 
(Giguere et al., 1987; Petkovich et al., 1987). Based on the empirical observation that RA 
induced neural differentiation in P19 tetracarcinoma cells, RA was used to enhance neural 
lineage commitment in ESCs (Bain et al., 1995). Today, RA is often used to enhance neural 
lineage commitment in ESC to generate neurospheres containing neural stem cells and for 
the subsequent terminal differentiation of neurospheres to produce neurons, 
oligodendrocytes and astrocytes. Therefore, the use of RA to induce neural differentiation in 
ESCs was rationalized on empirical observation of their effects on EC cells and this preceded 
the cloning of RA receptors and our understanding of its role in embryonic development. 
To date, there is little evidence that RA plays a significant role in neural differentiation 
during gastrulation. The first RA signaling in the gastrulating vertebrate embryo occurs in 
the posterior mesodermal cells when RA is first synthesized by retinaldehyde 
dehydrogenase 2 (RALDH2) (Niederreither et al., 1997). There is however no RA signaling 
in the anterior regions of the embryo due to the presence of RA metabolizing enzymes such 
as CYP26A1 and CYP26C1 (Hernandez et al., 2007; Ribes et al., 2007; Uehara et al., 2007). In 
fact, RA receptors in the prospective head region of the Xenopus gastrula function as 
transcriptional repressors to prevent inappropriate activation of genes acting as posterior 
determinants. Also, the absence of endogenous RA synthesis in mice affect primarily 
forebrain development but did not compromise the early neural lineage commitment or 
differentiation (Natalia Molotkova et al., 2007; N. Molotkova et al., 2005; Niederreither et al., 
2000; Sirbu et al., 2005). In fact, the pathway for neural differentiation during embryonic 
development could not have informed on the usefulness of insulin, triiodothyroidin, EGF 
and FGF in enhancing the in vitro proliferation and differentiation of ESC-derived 
oligodendrocyte precursors and increase oligodendrocyte survival.  
The second ESC-derived cell type most likely to be tested in man is Advanced Cell 
Technology’s retinal pigment epithelial (RPE) cells which has been given FDA clearance to 
initiate a Phase I/II multicenter clinical trial to treat patients with Dry AMD. The derivation 
of these RPE cells relies primarily on spontaneous differentiation of hESCs (Klimanskaya et 
al., 2004). RPE cells are formed as colonies of pigmented cells when hESCs undergo 
spontaneous differentiation by FGF2 withdrawal or embryoid body formation. These 
colonies of pigmented cells were then picked and expanded using very unremarkable 
culture medium.  
2.3.5 Strategizing differentiation of ESC for therapeutic applications 
The progress of ESC-derived oligodendrocytes and RPE cells to clinical testing attests to the 
robustness and efficiency of the empirically-driven differentiation protocols. In contrast, 
differentiation of ESCs by meticulous mapping on embryonic development pathway has not 
yielded cells that are ready for clinical testing. Despite this dichotomy in outcomes, there is 
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still a prevalent belief that high fidelity recapitulation of embryonic development process is 
the route to generate the most physiologically relevant cells. Embryonic development is a 
time tested success with defined milestones. In contrast, an empirically driven 
differentiation strategy is an inherently inefficient chance event.  
The success of a differentiation strategy based on embryonic development is predicated not 
only on the elucidation but also the recapitulation of the highly dynamic temporal and 
spatial changes in the embryonic microenvironment that is influenced by both intra- and  
 
 
Fig. 2. Strategies for differentiation of ESCs into therapeutically useful cell types. The 
strategies currently being used could be broadly classified into a developmental or an 
empirical approach. The developmental approach (upper panel) to produce a desired cell 
type (green stars) relies on the recapitulation of the developmental pathway (blue arrows) 
during embryogenesis that produces that desired cell type. The general expectation is that 
identifying the cues that direct the developmental process during embryogenesis and 
recapitulating these cues spatially and temporally in vitro will be most optimal in yielding 
physiologically functional cell type (e.g. pancreatic insulin-producing cells). The empirical 
approach involves the differentiation of ESCs either spontaneously, or using novel factors 
identified empirically, such as through high-throughput molecular screening or in vitro cell 
studies (e.g. neural induction of EC cells by RA). These factors may or may not play a role in 
development.    
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extra-embryonic factors. Notwithstanding this, translating such a complex differentiation 
strategy to a scalable commercially viable manufacturing process will be an equally 
confounding unknown. On the other hand, developing a differentiation strategy using an 
empirical approach is a chance process of trial and error and fortuitous observation. This 
inherent inefficiency can be circumvented by high throughput screens to identify inducing 
molecules or combinations of molecules. There is also a likelihood that such a strategy 
would provide for a potentially scalable manufacturing process that will support clinical 
applications. 
3. ESC therapeutics: cell versus biologic   
A much overlooked form of ESC-derived therapeutics is biological products or biologics 
from ESC. To date, the predominant or only forms of ESC-derived therapeutics that are 
being evaluated are primarily cell-based. The capacity of ESC to undergo spontaneous 
differentiation in a minimal culture medium to form tissues from all three germ layers 
suggest that differentiating ESCs can produce an inductive and sustaining 
microenvironment for the various cell types that are being formed. It is conceivable that 
some of this microenvironment may also induce or sustain some tissue regeneration and 
repair in adult. However capturing this microenvironment and translating it to a scalable 
manufacturing process would be a challenge. 
Biologic-based therapeutics have several advantages over cell-based therapies. Biologics 
eliminates the need to preserve viability during manufacture, storage and transport, and 
administration to the patient. This substantially reduces the cost and complexity of 
production and delivery. Maintaining cell viability before and after transplantation has 
always been an important consideration in cell-based therapy. Although preserving the 
activity of biologics is not a minor consideration, it is, nevertheless more tractable than 
preserving cell viability. Cell therapy is generally a permanent or long term therapeutic 
sustained by the replicative capacity of the transplanted cells with little recourse for 
termination of therapy except when removal of the graft is possible. In contrast to biologics, 
cell therapy presents increased risks of tumor formation and acute immunological rejections. 
All things considered, ESC-based biologics is an attractive alternative to develop ESC-based 
therapeutics.  
As an illustration of a potential ESC-derived biologic, we have demonstrated that 
mesenchymal stem cells derived from hESCs (Lian et al., 2007) secrete factors (Sze et al., 
2007) that are cardioprotective in pig and mouse models of myocardial 
ischemia/reperfusion injury (Timmers et al., 2008). The active component in this secretion 
was small lipid vesicles of 50-100nm known as exosomes (Lai et al., 2010). Immortalization 
of these mesenchymal stem cells did not compromise the production or activity of the 
exosomes (T.S. Chen et al., 2011). These studies provided for the development of a 
sustainable scalable manufacturing process to produce potentially therapeutic exosomes for 
testing in the clinic.  
4. Conclusion 
ESC is a versatile cell that has exerted significant impact on our understanding and 
investigation of cell biology, differentiation and development. It has provided exciting 
possibilities for the treatment of highly intractable diseases. As the first ESC-derived cell 
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type makes its way into clinical testing, there is an apprehensive hope that ESC will justify 
its hype not only as a therapeutic agent but one that will treat a multitude of intractable 
diseases as wide ranging as its differentiation potential. The establishment of iPSC 
technology by Shinya Yamanaka (Takahashi & Yamanaka, 2006) represents a paradigm shift 
in not only our understanding of stem cell biology but also in overcoming the ethical and 
immune challenges that had stymied the translation of ESC into clinical applications. His 
approach of re-programming terminally differentiated cells into pluripotent stem cells 
contradicted fundamental principles in developmental biology. This approach of exploring 
beyond the obvious and logical using empirical and experimental strategies may be 
necessary to transcend this current bottleneck in generating the quantity and quality of ESC-
derived cells for therapy. 
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